Abstract
To date, many potent metal-based anticancer drugs have been developed and many drug delivery systems have been exploited to improve the targeting and decrease the side effects of anticancer drugs. Human serum albumin (HSA) binding contributes significantly to the discovery of new drug candidates because binding of drugs to HSA strongly influences their pharmacokinetic behaviour. Moreover, HSA is widely used in the clinical setting as a drug delivery system due to its potential for improving targeting while decreasing the side effects of drugs. This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications.
Keywords: Albumin, metal-based anticancer drugs, interaction of protein-ligand, drug carrier.
Current Pharmaceutical Design
Title:Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Volume: 21 Issue: 14
Author(s): Yi Gou, Yao Zhang, Feng Yang and Hong Liang
Affiliation:
Keywords: Albumin, metal-based anticancer drugs, interaction of protein-ligand, drug carrier.
Abstract: To date, many potent metal-based anticancer drugs have been developed and many drug delivery systems have been exploited to improve the targeting and decrease the side effects of anticancer drugs. Human serum albumin (HSA) binding contributes significantly to the discovery of new drug candidates because binding of drugs to HSA strongly influences their pharmacokinetic behaviour. Moreover, HSA is widely used in the clinical setting as a drug delivery system due to its potential for improving targeting while decreasing the side effects of drugs. This review not only provides a brief outline of the properties of HSA carriers but also provides an overview of the binding and anticancer characteristics of platinum-/ruthenium-based anticancer drugs to HSA that may guide the rational designing and development of metal-based drugs and HSA-based carriers for clinical applications.
Export Options
About this article
Cite this article as:
Gou Yi, Zhang Yao, Yang Feng and Liang Hong, Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs, Current Pharmaceutical Design 2015; 21 (14) . https://dx.doi.org/10.2174/1381612821666150302114739
DOI https://dx.doi.org/10.2174/1381612821666150302114739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Drug Delivery Letters Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Lymnaea EGF and Gigantoxin I, Novel Invertebrate Members of the Epidermal Growth Factor Family
Current Pharmaceutical Design Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Injectable Thermosensitive Chitosan/Glycerophosphate-Based Hydrogels for Tissue Engineering and Drug Delivery Applications: A Review
Recent Patents on Drug Delivery & Formulation Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets
Current Drug Targets The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Nutrition and NSCLC; Should We Administer Food Supplements?
Current Pharmaceutical Design Patent Selections :
Recent Patents on Biomarkers